Back to top
more

IDEAYA Biosciences (IDYA)

(Delayed Data from NSDQ)

$37.71 USD

37.71
2,126,872

-0.74 (-1.92%)

Updated May 24, 2024 04:00 PM ET

After-Market: $37.68 -0.03 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IDYA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

IDEAYA Biosciences, Inc. [IDYA]

Reports for Purchase

Showing records 141 - 160 ( 169 total )

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 141

08/13/2020

Company Report

Pages: 8

2Q20 Results; First Synthetic Lethality Candidate Could Reach the Clinic in 1H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 142

08/12/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 143

08/12/2020

Company Report

Pages: 6

2Q20 Earnings - $300M in Cash Should Accelerate Clinical Development

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 144

07/31/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 145

07/30/2020

Company Report

Pages: 6

GSK''s Highlighting of Ideaya''s Synthetic Lethality Pipeline Speaks Loads

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 146

07/17/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 147

07/16/2020

Daily Note

Pages: 3

Criteria Met for Expansion in Phase 2 Basket Trial in Skin Melanoma

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 148

07/16/2020

Company Report

Pages: 6

Update Highlights Broader Market Opportunity for IDE196. Readout in 1H21.

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 149

07/10/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 150

07/09/2020

Daily Note

Pages: 3

First Patient Dosed in Combination Trial of IDE196 and Mektovi for Metastatic Uveal Melanoma

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 151

07/09/2020

Company Report

Pages: 5

First Patient Dosed in Phase 1 Combo Trial of IDE196 + Binimetinib

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 152

06/24/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 153

06/23/2020

Company Report

Pages: 7

AACR Updates Provide Detailed Insights Into Ideaya''s Pipeline Potential

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 154

06/17/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 155

06/17/2020

Company Report

Pages: 8

Potential $3 Billion Partnership With GSK for Preclinical Synthetic Lethality Programs; Raising PT to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 156

06/16/2020

Company Report

Pages: 7

Synthetic Lethality Pipeline Enters the Spotlight - Increasing PT to $23

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 157

06/09/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 158

06/08/2020

Daily Note

Pages: 3

IDE397 Chosen for MAT2A Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 159

06/08/2020

Company Report

Pages: 5

MAT2A Candidate Nominated and IND Submission Remains on Track for 4Q20

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: IDEAYA Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 160

05/20/2020

Daily Note

Pages: 12

AACR Abstracts and Meeting Planner

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party